Description
Valcyte 450 mg Tablets – Valganciclovir
Valcyte 450 mg is a prescription antiviral tablet that doctors prescribe for two specific, serious conditions caused by cytomegalovirus (CMV): CMV retinitis in adult patients with AIDS, and CMV disease prevention in solid organ transplant recipients. At Ahmad Medico, Pakistan’s premier online pharmacy, you get an authentic, imported supply of this medication, delivered with professional care to your doorstep.
What Is Valcyte and How Does It Work?
Each Valcyte tablet contains 450 mg of valganciclovir, a prodrug that your body rapidly converts to ganciclovir after absorption. Ganciclovir is the active compound that actually fights the virus. It works by inhibiting the CMV DNA polymerase enzyme, which the virus needs to replicate itself. Without this enzyme functioning, the cytomegalovirus cannot multiply and spread to healthy tissue.
Valcyte tablets are pink, film-coated, oval-shaped, with “VGC” imprinted on one side and “450” on the other. Each tablet contains 496.3 mg of valganciclovir hydrochloride, equivalent to 450 mg of valganciclovir free base. The bioavailability of ganciclovir from Valcyte, when taken with food, reaches approximately 60%, which is substantially higher than that of older oral ganciclovir capsules.
Valcyte 450 mg Uses
According to the FDA-approved prescribing information, Valcyte has two primary indications:
- CMV Retinitis in AIDS Patients: Doctors prescribe it for the treatment of CMV retinitis, a viral infection of the retina, in adults with advanced HIV disease (AIDS). Left untreated, CMV retinitis can cause permanent blindness.
- CMV Disease Prevention in Organ Transplant Recipients: Valcyte is also indicated for the prevention of CMV disease in adult patients who receive a kidney, heart, or kidney-pancreas transplant and who are at high risk, specifically when the donor tests CMV-seropositive and the recipient is CMV-seronegative.
Dosage & Administration
Your doctor will set your exact dose based on your condition, kidney function, and individual health profile. The standard adult dosages, as outlined in the FDA prescribing label, are:
For CMV Retinitis:
- Induction phase: 900 mg (two 450 mg tablets) twice daily for 21 days, taken with food
- Maintenance phase: 900 mg (two 450 mg tablets) once daily, taken with food
For CMV Prevention After Transplant:
- 900 mg (two 450 mg tablets) once daily, taken with food, starting within 10 days of transplantation
Important administration points:
- Always take Valcyte with food. Food significantly increases the absorption of the drug into your bloodstream.
- Do not break or crush the tablets. Swallow them whole. Contact with broken tablet powder on your skin or eyes requires immediate washing with soap and water or plain water, respectively.
- Stay well-hydrated throughout your course of treatment to protect your kidneys.
- Adults should use Valcyte tablets, not the oral solution, which is formulated for pediatric use.
- If you have reduced kidney function (renal impairment), your doctor will adjust your dose based on your creatinine clearance. Do not self-adjust.
Side Effects
Valcyte carries a significant side effect profile, and your doctor will monitor your blood counts regularly during treatment. The most commonly reported adverse reactions, occurring in at least 20% of patients in clinical trials, include diarrhea, fever (pyrexia), fatigue, nausea, tremor, headache, and insomnia. Hematological abnormalities are equally important to watch for, including neutropenia, anemia, leukopenia, and thrombocytopenia.
Serious adverse events reported include:
- Severe bone marrow suppression, including aplastic anemia
- Acute kidney failure, particularly in elderly patients or those on nephrotoxic medicines
- Potential for cancer development, given ganciclovir’s mutagenic properties in animal studies
Contact your doctor immediately if you notice unusual bruising, unexplained bleeding, persistent fever, or signs of kidney problems such as decreased urination.
Precautions
Before you start Valcyte, there are several critical precautions your prescribing doctor will review with you:
- Pregnancy: Valcyte is classified as a potential teratogen in humans. Animal studies show embryo-fetal mortality and birth defects at exposures comparable to therapeutic human doses. Women of reproductive potential must complete a pregnancy test before starting treatment. Use effective contraception during therapy and for at least 30 days after the last dose.
- Breastfeeding: Do not breastfeed while on Valcyte. The CDC advises HIV-positive mothers against breastfeeding regardless, and the drug’s risk to nursing infants makes breastfeeding doubly inadvisable.
- Fertility: In males, Valcyte may cause temporary or permanent suppression of sperm production. Men should use barrier contraception during treatment and for at least 90 days after the final dose.
- Hematologic Monitoring: Your doctor should not start Valcyte if your absolute neutrophil count is below 500 cells/µL, platelet count is below 25,000/µL, or hemoglobin is below 8 g/dL. Blood counts require regular monitoring throughout treatment.
- Renal Function: Since ganciclovir clears through the kidneys, regular monitoring of serum creatinine is essential. Patients with pre-existing kidney impairment need dose adjustments.
- Drug Interactions: Tell your doctor about every medication you take. Notable interactions include didanosine (increased risk of pancreatitis), probenecid (raises ganciclovir blood levels), and any other myelosuppressive or nephrotoxic drugs.
Valcyte 450 mg Price in Pakistan – Ahmad Medico
Valcyte 450 mg tablets (pack of 60) are available at Ahmad Medico at Rs. 105,000. Given that this is an imported, specialist antiviral medication for conditions as serious as CMV retinitis and post-transplant CMV disease, Ahmad Medico makes it accessible to patients across Pakistan with reliable, nationwide delivery.
This information is for educational purposes. Valcyte is a prescription-only medication. Always take it under the direct supervision of a qualified physician.
